GlassScriptPhysician profile
Donna Payne Smith
NPI 1053382333
$1,354.83
in general payments reported to CMS, 2019-2025
24 companies · $221 in 2025
The $221 reported for 2025 was more than what 76% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $49.24 · 2021: $199 · 2022: $231 · 2023: $255 · 2024: $191 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $281.76 | 2019-2025 | |
| Glaxosmithkline, LLC. | $152.58 | 2019-2023 | Pediarix, Bexsero, Rotarix |
| Sanofi Pasteur INC. | $152.06 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $94.13 | 2021-2024 | Vaxelis, M-M-R II, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $82.66 | 2024-2025 | |
| Sobi, INC | $78.01 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $66.49 | 2023-2024 | Qelbree, Qelbree |
| Alexion Pharmaceuticals, INC. | $64.28 | 2021-2023 | Strensiq |
| Alk-Abello, INC | $53.52 | 2025 | Neffy, Grastek, Odactra |
| Ironshore Pharmaceuticals INC. | $43.29 | 2019-2024 | |
| Cranial Technologies, INC | $36.09 | 2022-2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $34.31 | 2022-2024 | Flumist Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $26.72 | 2022 | |
| Biofire Diagnostics, LLC | $23.07 | 2019 | |
| Corium, LLC | $20.69 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $19.56 | 2025 | Wegovy |
| Azurity Pharmaceuticals, INC. | $18.75 | 2022 | |
| Neos Therapeutics, LP | $17.25 | 2020 | |
| Cepheid | $16.78 | 2025 | Genexpert |
| Collegium Pharmaceutical, INC. | $16.73 | 2025 | Jornay Pm |
| Shire North American Group INC | $16.44 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.50 | 2021 | |
| Mission Pharmacal Company | $13.51 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.